Autres langues Precision BioSciences, Inc.

Actions

DTIL

US74019P2074

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 02/05/2024			Varia. 5j.	Varia. 1 janv.
10,84 ^USD	+3,44%		+10,39%	-1,00%

30/04	PRECISION BIOSCIENCES, INC. : Opinion positive de Guggenheim	ZM
16/04	Transcript : Precision BioSciences, Inc. - Special Call

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Precision BioSciences Announces Late-Breaking Poster Presentation at the European Association for Study of the Liver (EASL) Congress 2024	01/05
Precision BioSciences Opts to Regain Rights to 3 Programs From Eli Lilly Unit Collaboration	16/04
Precision BioSciences Announces Return of Programs and Conclusion of Collaboration with Prevail Therapeutics	16/04
Precision BioSciences, Inc. Announces Return of Programs and Conclusion of Collaboration with Prevail Therapeutics	16/04
Precision BioSciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	27/03
Precision BioSciences, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	27/03
Precision BioSciences: Q4 Earnings Snapshot	27/03
Earnings Flash (DTIL) PRECISION BIOSCIENCES Posts Q4 Revenue $7M	27/03
Precision BioSciences Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Provides Business Update	27/03
Precision BioSciences to Report Fourth Quarter and Fiscal Year 2023 Results on March 27, 2024	20/03
Precision BioSciences Presents Preclinical Data Highlighting PBGENE-PMM as a Potential Therapy for Primary Mitochondrial Myopathy	19/03
IECURE SECURES APPROVAL FROM U.K. MEDICINES AND HEALTHCARE PRODUCTS REGULATORY AGENCY TO EXPAND THE OTC-HOPE STUDY OF ECUR-506	07/03
Precision BioSciences Announces MHRA Approval for Partner iECURE to Expand Phase 1/2 Clinical Trial of ARCUS Gene Editing Program in OTC Deficiency	06/03
Precision BioSciences Announces MHRA Approval for Partner iECURE to Expand Phase 1/2 Clinical Trial of ARCUS Gene Editing Program in OTC Deficiency	06/03
Precision BioSciences Announces $40.0 Million Offering of Common Stock and Warrants	04/03
Precision BioSciences Launches $40 Million Public Offering; Shares Slump	01/03
Precision BioSciences Announces $40.0 Million Offering of Common Stock and Warrants	01/03
Precision BioSciences Announces Proposed Public Offering of Common Stock and Warrants	29/02
Precision BioSciences Announces Non-Exclusive Patent License Agreement with Caribou Biosciences	20/02
Precision BioSciences, Inc. Announces Non-Exclusive Patent License Agreement with Caribou Biosciences	20/02

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Precision BioSciences, Inc.

Actions

DTIL

US74019P2074

Autres langues

Filtres